Implication of polygenic risk in platelet reactivity in patients with acute coronary syndrome treated with clopidogrel

Clopidogrel is the most commonly used antiplatelet in patients with acute coronary syndrome (ACS) for the prevention of atherothrombotic events. It has been estimated that the heritability of the clopidogrel response phenotype is 70%, indicating an important influence of genetic variance, potentially responsible for thrombotic events, hemorrhages and even death. Few studies have incorporated large-scale genomic analysis for the simultaneous evaluation of genes responsible for clopidogrel metabolism and the polygenic impact of molecular variants on antiplatelet aggregation.